Silence Therapeutics Plc ADR (SLN)

$6.96 -0.17 (-2.38%)
Market Cap 328.75M
Revenue (ttm) 43.26M
Net Income (ttm) -45.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -104.74%
Debt to Equity Ratio 0.00
Volume 248,100
Avg Vol 210,182
Day's Range N/A - N/A
Shares Out 47.23M
Stochastic %K 68%
Beta 1.35
Analysts Strong Sell
Price Target $33.80

Company Profile

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treat...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 20 3457 6900
Address:
72 Hammersmith Road, London, United Kingdom
LIGator
LIGator Dec. 5 at 12:45 AM
$SLN over 600,000 shares and up 12%. Just a normal day 😳
0 · Reply
_www_larval_com_
_www_larval_com_ Dec. 4 at 8:57 PM
$SLN 4%[12%] $NDRA 3%[-8%] most notable movement into the final minutes of trading.
0 · Reply
xbibackto1milly
xbibackto1milly Dec. 3 at 4:51 PM
$SLN trash! xbi flying this is red. 4s soon
0 · Reply
xbibackto1milly
xbibackto1milly Dec. 2 at 4:50 PM
$SLN you've been warned
0 · Reply
13Tpro
13Tpro Nov. 26 at 8:17 PM
$SLN This company is undervalued, the mc should be at least$1B. RNA interference/ siRNA is the technology BP wants. Dicerna and Avidity were bought out. SLN will be next IMO
0 · Reply
xbibackto1milly
xbibackto1milly Nov. 20 at 5:49 PM
$SLN 5s soon
0 · Reply
xbibackto1milly
xbibackto1milly Nov. 19 at 7:43 PM
$SLN lmao
0 · Reply
xbibackto1milly
xbibackto1milly Nov. 18 at 12:17 PM
$SLN tank city coming
0 · Reply
xbibackto1milly
xbibackto1milly Nov. 17 at 8:13 PM
$SLN 6.66 is fitting bc this is the devil 😈
0 · Reply
xbibackto1milly
xbibackto1milly Nov. 17 at 4:30 PM
$SLN lol pig
0 · Reply
Latest News on SLN
Silence Therapeutics: Divesiran Targets High-Burden PV

Nov 18, 2025, 6:03 AM EST - 18 days ago

Silence Therapeutics: Divesiran Targets High-Burden PV

Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Nov 12, 2025, 8:00 AM EST - 24 days ago

Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 7:30 AM EST - 4 weeks ago

Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)

Oct 23, 2025, 7:30 AM EDT - 6 weeks ago

Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV)

Silence Therapeutics Plc (SLN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 10:01 PM EDT - 3 months ago

Silence Therapeutics Plc (SLN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Silence Therapeutics to Participate in September Investor Conferences

Sep 2, 2025, 8:00 AM EDT - 3 months ago

Silence Therapeutics to Participate in September Investor Conferences

Silence (SLN) Q2 Revenue Drops 71%

Aug 7, 2025, 10:58 AM EDT - 4 months ago

Silence (SLN) Q2 Revenue Drops 71%

Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 7, 2025, 7:30 AM EDT - 4 months ago

Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

Jun 12, 2025, 4:01 PM EDT - 6 months ago

Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera

Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 8, 2025, 8:00 AM EDT - 7 months ago

Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

May 6, 2025, 7:45 AM EDT - 7 months ago

Silence Therapeutics Welcomes Tim McInerney to Board of Directors

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

Mar 5, 2025, 8:00 AM EST - 9 months ago

Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference

Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript

Feb 28, 2025, 11:59 AM EST - 10 months ago

Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 7:30 AM EST - 10 months ago

Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

Feb 13, 2025, 8:00 AM EST - 10 months ago

Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025

Top 3 Health Care Stocks That May Explode In Q4

Dec 18, 2024, 7:46 AM EST - 1 year ago

Top 3 Health Care Stocks That May Explode In Q4

OLMA

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

Dec 9, 2024, 7:30 AM EST - 1 year ago

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

Nov 19, 2024, 3:34 PM EST - 1 year ago

Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst

Top 3 Health Care Stocks You'll Regret Missing In Q4

Nov 19, 2024, 7:52 AM EST - 1 year ago

Top 3 Health Care Stocks You'll Regret Missing In Q4

AMRN TERN

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

Nov 18, 2024, 2:30 PM EST - 1 year ago

Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 14, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Nov 13, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy'

Sep 8, 2024, 9:13 AM EDT - 1 year ago

Silence Therapeutics' RNAi Pipeline: Zerlasiran's Game-Changer Potential Is A 'Buy'

Silence: Additional siRNA Drug Data Leads To Next Stages Of Development

Sep 5, 2024, 2:18 PM EDT - 1 year ago

Silence: Additional siRNA Drug Data Leads To Next Stages Of Development

Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 15, 2024, 7:30 AM EDT - 1 year ago

Silence Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Jun 27, 2024, 7:30 AM EDT - 1 year ago

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration

Jun 24, 2024, 8:30 AM EDT - 1 year ago

Silence Therapeutics Achieves $2 Million Research Milestone Payment from Hansoh Pharma Collaboration

Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results

Jun 21, 2024, 2:31 PM EDT - 1 year ago

Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

Jun 20, 2024, 7:30 AM EDT - 1 year ago

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a)

Silence Therapeutics to Present at Jefferies Global Healthcare Conference

May 30, 2024, 8:30 AM EDT - 1 year ago

Silence Therapeutics to Present at Jefferies Global Healthcare Conference

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

May 16, 2024, 8:30 AM EDT - 1 year ago

Silence Therapeutics Reports First Quarter 2024 Results and Highlights Pipeline Progress

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Apr 30, 2024, 8:30 AM EDT - 1 year ago

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright 2nd Annual BioConnect Investor Conference

Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

Apr 29, 2024, 8:30 AM EDT - 1 year ago

Silence Therapeutics Announces Retirement of Alistair Gray from Board of Directors

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Apr 8, 2024, 11:48 AM EDT - 1 year ago

Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Silence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 10:01 AM EDT - 1 year ago

Silence Therapeutics plc (SLN) Q4 2023 Earnings Call Transcript

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Mar 13, 2024, 7:05 AM EDT - 1 year ago

Silence Therapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Mar 13, 2024, 7:00 AM EDT - 1 year ago

Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

Feb 28, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results on March 13, 2024

Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look

Feb 24, 2024, 8:53 PM EST - 1 year ago

Silence Therapeutics: Multiple 2024 Catalysts Make This mRNA Biotech Worth A Look

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Feb 23, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Following the Initiation of Phase 1 Trial

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

Feb 5, 2024, 8:00 AM EST - 1 year ago

Silence Therapeutics Announces Oversubscribed $120 Million Private Placement

Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024, 7:00 AM EST - 2 years ago

Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments

Dec 1, 2023, 7:00 AM EST - 2 years ago

Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

Nov 14, 2023, 7:00 AM EST - 2 years ago

Silence Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Nov 8, 2023, 7:00 AM EST - 2 years ago

Silence Therapeutics to Present at Jefferies London Healthcare Conference

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

Nov 1, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

Silence Therapeutics to Participate in Fireside Chat at Chardan's 7th Annual Genetic Medicines Conference

Sep 26, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics to Participate in Fireside Chat at Chardan's 7th Annual Genetic Medicines Conference

Silence Therapeutics Reports Second Quarter 2023 Results

Aug 16, 2023, 7:00 AM EDT - 2 years ago

Silence Therapeutics Reports Second Quarter 2023 Results

LIGator
LIGator Dec. 5 at 12:45 AM
$SLN over 600,000 shares and up 12%. Just a normal day 😳
0 · Reply
_www_larval_com_
_www_larval_com_ Dec. 4 at 8:57 PM
$SLN 4%[12%] $NDRA 3%[-8%] most notable movement into the final minutes of trading.
0 · Reply
xbibackto1milly
xbibackto1milly Dec. 3 at 4:51 PM
$SLN trash! xbi flying this is red. 4s soon
0 · Reply
xbibackto1milly
xbibackto1milly Dec. 2 at 4:50 PM
$SLN you've been warned
0 · Reply
13Tpro
13Tpro Nov. 26 at 8:17 PM
$SLN This company is undervalued, the mc should be at least$1B. RNA interference/ siRNA is the technology BP wants. Dicerna and Avidity were bought out. SLN will be next IMO
0 · Reply
xbibackto1milly
xbibackto1milly Nov. 20 at 5:49 PM
$SLN 5s soon
0 · Reply
xbibackto1milly
xbibackto1milly Nov. 19 at 7:43 PM
$SLN lmao
0 · Reply
xbibackto1milly
xbibackto1milly Nov. 18 at 12:17 PM
$SLN tank city coming
0 · Reply
xbibackto1milly
xbibackto1milly Nov. 17 at 8:13 PM
$SLN 6.66 is fitting bc this is the devil 😈
0 · Reply
xbibackto1milly
xbibackto1milly Nov. 17 at 4:30 PM
$SLN lol pig
0 · Reply
xbibackto1milly
xbibackto1milly Nov. 14 at 7:53 PM
$SLN red lol
0 · Reply
xbibackto1milly
xbibackto1milly Nov. 14 at 6:02 PM
$SLN 🗑️
0 · Reply
xbibackto1milly
xbibackto1milly Nov. 14 at 5:07 PM
$SLN 5.5% diff w xbi today what a pos
0 · Reply
xbibackto1milly
xbibackto1milly Nov. 14 at 5:04 PM
$SLN trash! xbi flying too
0 · Reply
xbibackto1milly
xbibackto1milly Nov. 14 at 3:04 PM
$SLN going no where w this mgmt
0 · Reply
topstockalerts
topstockalerts Nov. 13 at 12:06 PM
Pre Market Top Gainers PT2 $LVLU $TRUG $CLBT $SGBX $SLN
1 · Reply
xbibackto1milly
xbibackto1milly Nov. 12 at 7:58 PM
$SLN trash
0 · Reply
xbibackto1milly
xbibackto1milly Nov. 12 at 2:23 PM
$SLN will lose all its gains from yesterday today
0 · Reply
xbibackto1milly
xbibackto1milly Nov. 10 at 7:35 PM
$SLN trash
0 · Reply
Florestan
Florestan Nov. 7 at 5:14 PM
$SLN what's our take here? I think the PV program has a lot of value and is unloved by the market (maybe because it's not in the news/mainstream/hyped). The Lpa program needs a partner.
1 · Reply
xbibackto1milly
xbibackto1milly Nov. 7 at 3:43 PM
$SLN lol what a fn pos!!
0 · Reply
d_risk
d_risk Nov. 6 at 4:15 PM
$SLN - Silence Therapeutics Plc American Depository Share - 10Q - Updated Risk Factors SLN’s latest 10-Q flags heightened data privacy and security risks amid stricter global rules and AI threats, plus expanded US drug pricing controls, new UK clinical trial laws, and looming EU reforms that could speed up generic competition. #Biotechnology #RegulatoryReform #ClinicalTrials #DrugPricing #DataPrivacy 🟢 Added 🟠 Removed https://d-risk.ai/SLN/10-Q/2025-11-06
0 · Reply